Merck & Co Inc (MRK)
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Precio Actual
Capitalización
Desviación
Y/Y Growth
EBIT Margin
ROIC
PEG Ratio
ROE
3Y EPS Growth
Dividend Yield
Net Debt / EBITDA
Proyecciones CAGR
Proyecciones de tasa de crecimiento anual compuesta basadas en diferentes modelos de valoración. CAGR EV/FCF es la métrica principal.
Múltiplos de Valoración
Múltiplos de valoración utilizados para las estimaciones de CAGR y precios objetivo.
Gráfico de Evolución del Precio
Precios Objetivo FCF
Precios futuros estimados de la acción basados en proyecciones de flujo de caja libre.
Reverse DCF
Rentabilidad mínima que exiges a tu inversión. Refleja el coste de oportunidad y el riesgo.
Múltiplo EV/FCF al que se valorará la empresa al final del periodo de proyección.
Notas
Rendimiento Histórico vs. Índices
Rendimiento anual (YTD) de la acción comparado con índices y materias primas de referencia.
| Año | Rendimiento MRK | Rendimiento Bitcoin | Rendimiento vs. Bitcoin | Rendimiento Gold | Rendimiento vs. Gold | Rendimiento Bono USA 7-10y | Rendimiento vs. Bono USA 7-10y | Rendimiento Bono USA 1-3y | Rendimiento vs. Bono USA 1-3y | Rendimiento Bono USA 20+y | Rendimiento vs. Bono USA 20+y | Rendimiento Dow Jones | Rendimiento vs. Dow Jones | Rendimiento S&P 500 | Rendimiento vs. S&P 500 | Rendimiento NASDAQ 100 | Rendimiento vs. NASDAQ 100 | Rendimiento MSCI World | Rendimiento vs. MSCI World | Rendimiento Russell 2000 | Rendimiento vs. Russell 2000 | Rendimiento STOXX Europe 600 | Rendimiento vs. STOXX Europe 600 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026 YTD en Vivo | 16.32% | -23.32% | +39.64% | 21.46% | -5.14% | 1.99% | +14.33% | 0.39% | +15.93% | 4.35% | +11.96% | 1.23% | +15.09% | 0.30% | +16.02% | -2.44% | +18.76% | 2.32% | +14.00% | 4.95% | +11.37% | 6.33% | +9.99% |
2025 | 6.14% | 110.77% | -104.63% | 26.96% | -20.81% | -3.73% | +9.87% | 0.05% | +6.09% | -11.17% | +17.31% | 12.80% | -6.66% | 24.01% | -17.87% | 30.78% | -24.64% | 17.88% | -11.74% | 10.80% | -4.66% | 5.50% | +0.64% |
2024 | -12.15% | 153.66% | -165.81% | 11.76% | -23.91% | -0.15% | -12.01% | 0.98% | -13.14% | -2.54% | -9.61% | 13.74% | -25.89% | 24.73% | -36.88% | 44.52% | -56.67% | 21.92% | -34.08% | 15.78% | -27.94% | 11.67% | -23.82% |
2023 | -1.91% | -65.23% | +63.32% | 0.78% | -2.69% | -15.93% | +14.02% | -5.00% | +3.09% | -31.00% | +29.10% | -9.40% | +7.49% | -19.95% | +18.05% | -33.89% | +31.99% | -19.70% | +17.79% | -22.50% | +20.59% | -13.29% | +11.38% |
2022 | 44.33% | 60.33% | -16.00% | -6.24% | +50.57% | -4.15% | +48.49% | -0.98% | +45.32% | -5.94% | +50.27% | 20.23% | +24.10% | 28.79% | +15.54% | 23.20% | +21.13% | 21.22% | +23.11% | 15.39% | +28.95% | 21.66% | +22.67% |
2021 | -0.73% | 301.93% | -302.65% | 23.90% | -24.63% | 8.33% | -9.05% | 2.02% | -2.74% | 15.12% | -15.85% | 6.02% | -6.74% | 15.29% | -16.02% | 41.75% | -42.48% | 12.94% | -13.67% | 18.48% | -19.21% | -4.64% | +3.91% |
2020 | -11.12% | 88.85% | -99.98% | 17.78% | -28.90% | 5.55% | -16.68% | 1.20% | -12.32% | 10.91% | -22.03% | 21.91% | -33.03% | 28.34% | -39.46% | 34.60% | -45.72% | 25.23% | -36.35% | 23.05% | -34.17% | 23.42% | -34.54% |
2019 | 20.31% | -71.79% | +92.10% | -3.12% | +23.43% | -0.97% | +21.28% | -0.24% | +20.55% | -3.17% | +23.48% | -6.03% | +26.34% | -7.01% | +27.32% | -5.30% | +25.61% | -11.16% | +31.47% | -13.00% | +33.31% | -13.42% | +33.73% |
2018 | 35.91% | 1,184.56% | -1,148.65% | 11.93% | +23.98% | 0.76% | +35.14% | -0.63% | +36.54% | 6.03% | +29.87% | 24.33% | +11.58% | 18.42% | +17.49% | 27.16% | +8.75% | 19.45% | +16.45% | 12.45% | +23.46% | 7.16% | +28.75% |
2017 | -6.45% | 1,184.56% | -1,191.01% | 11.93% | -18.38% | -1.15% | -5.30% | -0.02% | -6.43% | -1.91% | -4.54% | 24.33% | -30.78% | 18.42% | -24.87% | 27.16% | -33.61% | 19.45% | -25.91% | 12.45% | -18.90% | 7.16% | -13.61% |
| Media | 9.07% | 292.43% | -283.37% | 11.71% | -2.65% | -0.94% | +10.01% | -0.22% | +9.29% | -1.93% | +11.00% | 10.92% | -1.85% | 13.13% | -4.07% | 18.75% | -9.69% | 10.96% | -1.89% | 7.79% | +1.28% | 5.16% | +3.91% |
Historial de Valoración
Historial de cambios significativos en los factores de valoración y precios objetivo a lo largo del tiempo. Los valores resaltados indican un cambio respecto a la valoración anterior.
Fecha de Valoración | Y/Y Growth | EBIT Margin | Net Debt/EBITDA | P/E | EV/FCF | EV/EBITDA | EV/EBIT | Objetivo 2026 | Objetivo 2027 | Objetivo 2028 | Objetivo 2029 | Objetivo 2030 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2/6/2026 | 5.2% | 39.1% | 0.8x | 15x(38x) | 15x | 12x | 13x | $89.05 | $144.14 | $152.87 | $162.11 | $171.92 |
| 11/6/2025 | 4.4% | 41.4% | 0.8x | 11x(17x) | 11x | 8x | 9x | $93.75 | $95.79 | $102.33 | $107.38 | $112.68 |
| 10/8/2025 | 4.2% | 43% | 0.8x | 11x(17x) | 11x | 8x | 9x | $94.30 | $98.68 | $105.95 | $111.17 | $116.66 |
Historial de Dividendos
Evolución de los dividendos por acción pagados durante los últimos 10 años.Dividend Achiever - 10+ años de crecimiento continuo
| Año | Dividendo por Acción | Crecimiento |
|---|---|---|
| 2026 Actual | $3.24 | +5.19% |
| 2025 | $3.08 | +5.48% |
| 2024 | $2.92 | +5.80% |
| 2023 | $2.76 | +6.15% |
| 2022 | $2.60 | +6.56% |
| 2021 | $2.44 | +10.91% |
| 2020 | $2.20 | +14.58% |
| 2019 | $1.92 | +2.13% |
| 2018 | $1.88 | +2.17% |
| 2017 | $1.84 | - |
Análisis de Outperformance
Rendimiento histórico vs índices principales y métricas de consistencia
Outperformance Promedio vs Índices
Rendimiento promedio comparado con los principales índices del mercado
Evolución del Rendimiento Año a Año
Rendimiento histórico con marcadores de mejores y peores años
Consistencia de Rendimiento
Porcentaje de años con rendimientos positivos
MRK shows moderate consistency with positive returns in 50% of years.